• Nuwellis disclosed acceptance by Frontiers in Pediatrics of a retrospective study on anticoagulation during Aquadex ultrafiltration in critically ill children.
• Results were already generated in routine care, not a prospective trial; publication is pending following journal acceptance.
• The study found epoprostenol kept Aquadex circuits functioning without added bleeding risk or greater need for blood-pressure support.
• Findings support an alternative anticoagulation option for pediatric patients who may not be suitable for conventional approaches, potentially widening Aquadex use.
• Nuwellis funded open-access publication costs, not the conduct of the research.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuwellis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300800PRIMZONEFULLFEED9800591) on July 30, 2026, and is solely responsible for the information contained therein.